Navigation Links
Perrigo Announces Approval for Over-the-Counter Children's Cetirizine Oral Solution
Date:4/14/2008

ALLEGAN, Mich., April 14 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Children's Cetirizine Hydrochloride Oral Solution (Allergy) and Children's Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1mg/mL.

The product will be marketed under store brand labels and is comparable to McNeil Consumer Healthcare's Children's Zyrtec(R) Oral Solution, 1mg/mL, indicated for indoor and outdoor allergy and hives relief. According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the last 12 months ending December 2007 were approximately $80 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval reflects our strategy to be first to market with the important products that make quality healthcare more affordable for our customers."

The Company expects to begin shipping the product immediately.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... In China , we say ... Upgrade of China,s Healthy Strategy originates. ... for Economic and Social Development of the People,s ... the state council of the People,s Republic of ... industry development plan, identifying medical devices as one of the ...
(Date:1/18/2017)... Ximbio, a non-profit online one-stop-shop for the global ... first North American headquarters in Kendall Square, Cambridge, ... ... launch in October 2014 as a business unit of UK- ... the foundation Cancer Research UK. Ximbio.com allows scientists ...
(Date:1/18/2017)... and Drug Administration CSL CureVac Daiichi ... Drug Administration FORT Fresenius Pharmaceuticals Gamma ... GlaxoWellcome Global Influenza Programme Grippol ... Targeting Systems Indian Association of Paediatrics Janssen Pharmaceuticals ... Krka Pharmaceuticals Medicago Medicare ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Delaware farmer Rick Dickerson attended the 2017 ... of Laurel, farms about a thousand acres of soybeans, corn and wheat, and raises ... pumpkins and other vegetables for the fresh market. He also operates a roadside stand ...
(Date:1/18/2017)... and SHANGHAI, China – , ... ... Global public health organization NSF International has certified the first ... NSF/ANSI 53: Drinking Water Treatment Units – Health Effects, an ... verifies that MicroCeramics’ NanoNose Pitcher Filter System filters the water ...
(Date:1/18/2017)... ... January 18, 2017 , ... PrideStaff, a national, franchised ... Development, Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide Business ... top business leaders from across the globe, provides viewers an opportunity to find ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is an esteemed dentist who ... modern dental practice has two convenient office locations in Alexandria and Arlington, Virginia. Recently, ... for the Alexandria area. This award confirms the fact that Dr. Qureshi’s patients ...
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, ... Brake Technology (ABT), an innovative braking system that allows skaters of all levels ... one of the biggest concerns of beginner and intermediate skaters – learning how ...
Breaking Medicine News(10 mins):